Alzheimer’s disease is the sixth leading cause of death in the United States. Unfortunately, Alzheimer’s has not seen a new therapeutic drug approved in nearly two decades, and there’s never been a disease-modifying therapy.

Finding a treatment for Alzheimer’s requires urgency and resources, and I call on the U.S. Food and Drug Administration (FDA) to quickly but thoroughly review and act on symptomatic or disease-modifying Alzheimer’s treatments under consideration for approval.

American patients and their families deserve to have all the options available in confronting this terrible disease. When a drug is before the FDA, it should receive the greatest consideration that takes into account available scientific data and the preferences and lived experiences of patients and caregivers. FDA must follow the science, and it also must understand the impact of a new therapy on the millions of patients, families, and caregivers living with and experiencing Alzheimer’s and other dementias.

Tell the FDA to consider Alzheimer’s treatments quickly and to ensure patients and caregivers voices are heard throughout the process. 


UsAgainstAlzheimer | Privacy Policy

Tell the FDA to quickly approve promising new Alzheimer’s treatments!